Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308706077> ?p ?o ?g. }
- W4308706077 endingPage "e1004107" @default.
- W4308706077 startingPage "e1004107" @default.
- W4308706077 abstract "Background Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in the World Health Organization’s Unity protocol (WHO Unity) for general population seroepidemiological studies, to estimate the extent of population infection and seropositivity to the virus 2 years into the pandemic. Methods and findings We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between January 1, 2020 and May 20, 2022. The review protocol is registered with PROSPERO (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies—those aligned with the WHO Unity protocol—were extracted and critically appraised in duplicate, with risk of bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate underascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% low- and middle-income countries [LMICs]) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/subnational scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6 to 28.8] to 86.7% [84.6% to 88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3% to 11.0%] in June 2020 to 95.9% [92.6% to 97.8%] in December 2021, in European high-income countries [HICs]). After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0 to 9 years and adults 60+ were at lower risk of seropositivity than adults 20 to 29 ( p < 0.001 and p = 0.005, respectively). In a multivariable model using prevaccination data, stringent public health and social measures were associated with lower seroprevalence ( p = 0.02). The main limitations of our methodology include that some estimates were driven by certain countries or populations being overrepresented. Conclusions In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions." @default.
- W4308706077 created "2022-11-14" @default.
- W4308706077 creator A5014197487 @default.
- W4308706077 creator A5014440012 @default.
- W4308706077 creator A5015465867 @default.
- W4308706077 creator A5017468357 @default.
- W4308706077 creator A5022027663 @default.
- W4308706077 creator A5022907062 @default.
- W4308706077 creator A5023324131 @default.
- W4308706077 creator A5024530141 @default.
- W4308706077 creator A5027694435 @default.
- W4308706077 creator A5028155391 @default.
- W4308706077 creator A5033381977 @default.
- W4308706077 creator A5033873670 @default.
- W4308706077 creator A5034028198 @default.
- W4308706077 creator A5039903988 @default.
- W4308706077 creator A5040016196 @default.
- W4308706077 creator A5040302008 @default.
- W4308706077 creator A5046734602 @default.
- W4308706077 creator A5049072629 @default.
- W4308706077 creator A5049448850 @default.
- W4308706077 creator A5054311525 @default.
- W4308706077 creator A5075152204 @default.
- W4308706077 creator A5075577795 @default.
- W4308706077 creator A5075790654 @default.
- W4308706077 creator A5076547195 @default.
- W4308706077 creator A5083601552 @default.
- W4308706077 creator A5085850450 @default.
- W4308706077 creator A5086103218 @default.
- W4308706077 creator A5087462039 @default.
- W4308706077 creator A5088791956 @default.
- W4308706077 date "2022-11-10" @default.
- W4308706077 modified "2023-10-18" @default.
- W4308706077 title "Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies" @default.
- W4308706077 cites W1951724000 @default.
- W4308706077 cites W2119160928 @default.
- W4308706077 cites W2139168999 @default.
- W4308706077 cites W2156098321 @default.
- W4308706077 cites W2417616718 @default.
- W4308706077 cites W2571979973 @default.
- W4308706077 cites W2975424845 @default.
- W4308706077 cites W2978795816 @default.
- W4308706077 cites W2991792334 @default.
- W4308706077 cites W3020176834 @default.
- W4308706077 cites W3033536745 @default.
- W4308706077 cites W3042819477 @default.
- W4308706077 cites W3093667122 @default.
- W4308706077 cites W3099989333 @default.
- W4308706077 cites W3105076578 @default.
- W4308706077 cites W3111564425 @default.
- W4308706077 cites W3135657598 @default.
- W4308706077 cites W3137307037 @default.
- W4308706077 cites W3139820633 @default.
- W4308706077 cites W3155000349 @default.
- W4308706077 cites W3156230686 @default.
- W4308706077 cites W3160918102 @default.
- W4308706077 cites W3163246137 @default.
- W4308706077 cites W3163785571 @default.
- W4308706077 cites W3164088887 @default.
- W4308706077 cites W3164547793 @default.
- W4308706077 cites W3173470851 @default.
- W4308706077 cites W3175597068 @default.
- W4308706077 cites W3178962125 @default.
- W4308706077 cites W3201697469 @default.
- W4308706077 cites W3201865815 @default.
- W4308706077 cites W3204410170 @default.
- W4308706077 cites W3212693288 @default.
- W4308706077 cites W3212746439 @default.
- W4308706077 cites W4200228241 @default.
- W4308706077 cites W4200508064 @default.
- W4308706077 cites W4225920321 @default.
- W4308706077 doi "https://doi.org/10.1371/journal.pmed.1004107" @default.
- W4308706077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36355774" @default.
- W4308706077 hasPublicationYear "2022" @default.
- W4308706077 type Work @default.
- W4308706077 citedByCount "62" @default.
- W4308706077 countsByYear W43087060772021 @default.
- W4308706077 countsByYear W43087060772022 @default.
- W4308706077 countsByYear W43087060772023 @default.
- W4308706077 crossrefType "journal-article" @default.
- W4308706077 hasAuthorship W4308706077A5014197487 @default.
- W4308706077 hasAuthorship W4308706077A5014440012 @default.
- W4308706077 hasAuthorship W4308706077A5015465867 @default.
- W4308706077 hasAuthorship W4308706077A5017468357 @default.
- W4308706077 hasAuthorship W4308706077A5022027663 @default.
- W4308706077 hasAuthorship W4308706077A5022907062 @default.
- W4308706077 hasAuthorship W4308706077A5023324131 @default.
- W4308706077 hasAuthorship W4308706077A5024530141 @default.
- W4308706077 hasAuthorship W4308706077A5027694435 @default.
- W4308706077 hasAuthorship W4308706077A5028155391 @default.
- W4308706077 hasAuthorship W4308706077A5033381977 @default.
- W4308706077 hasAuthorship W4308706077A5033873670 @default.
- W4308706077 hasAuthorship W4308706077A5034028198 @default.
- W4308706077 hasAuthorship W4308706077A5039903988 @default.
- W4308706077 hasAuthorship W4308706077A5040016196 @default.
- W4308706077 hasAuthorship W4308706077A5040302008 @default.
- W4308706077 hasAuthorship W4308706077A5046734602 @default.
- W4308706077 hasAuthorship W4308706077A5049072629 @default.